Nintedanib - PF-ILD
Research payments
$37,070
Through program year 2020, $37,070 in research payments was reported against Nintedanib - PF-ILD, across 535 payments, paid by Boehringer Ingelheim Pharma GmbH & Co.KG.
- Paid by
- Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $211 | 1 |
| 2019 | Research | $36,860 | 534 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Robert Kaner New York, NY Named on 26 payments
- Maria Padilla New York, NY Named on 17 payments
- Oksana Shlobin Falls Church, VA Named on 16 payments
- Krishna Thavarajah Detroit, MI Named on 16 payments
- Neil Ettinger Chesterfield, MO Named on 15 payments
- Srihari Veeraraghavan Atlanta, GA Named on 15 payments
- Rebecca Bascom Hershey, PA Named on 15 payments
- Mary Scholand Salt Lake City, UT Named on 15 payments
- Milton Rossman Philadelphia, PA Named on 15 payments
- Lisa Jones Jacksonville, FL Named on 15 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.